Evaluating inflammation markers in diabetic cataract patients
Evaluation of Aqueous Humor DEL-1 and IL-17 Levels in Diabetic Cataract Patients
This study looks at the levels of certain inflammation markers in the eye fluid of diabetic cataract patients compared to non-diabetic patients to see how diabetes affects eye inflammation.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Sponsor | Uşak University Academic / other |
| Locations | 1 site (Uşak, Uşak) |
| Trial ID | NCT06995131 on ClinicalTrials.gov |
What this trial studies
This study compares the levels of DEL-1 and IL-17 in the aqueous humor of diabetic cataract patients to those of non-diabetic patients to understand the biochemical effects of diabetes-related inflammation in the eye. DEL-1 is involved in regulating inflammation and maintaining vascular health, while IL-17 is a cytokine that promotes inflammation. By analyzing these markers, the study aims to shed light on the inflammatory processes associated with cataracts in diabetic individuals. The findings could help in developing targeted therapies for diabetic eye diseases.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with cataracts who have had Type 2 Diabetes Mellitus for at least 5 years.
Not a fit: Patients with other ocular pathologies, autoimmune diseases, or those who have undergone previous eye surgeries may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment options for cataracts in diabetic patients.
How similar studies have performed: While similar studies have explored inflammation in diabetic eye diseases, the specific focus on DEL-1 and IL-17 in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cataract diagnosed and surgery planned * Patients without any other ocular pathology other than cataract. * Type 2 DM for at least 5 years in the diabetic group Exclusion Criteria: * Patients with previous intraocular surgery * Those with inflammatory eye diseases (e.g. uveitis) * Those with autoimmune diseases or systemic inflammatory diseases * Those receiving local or systemic steroid therapy * Those with severe systemic disease (e.g. advanced renal failure, malignancy)
Where this trial is running
Uşak, Uşak
- Uşak Training and Research Hospital — Uşak, Uşak, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Suzan Dogruya
- Email: sdogruya@hotmail.com
- Phone: +905322270732
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.